Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TransMedics Group, Inc. (TMDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TransMedics is a medical technology company focused on organ transplant therapy, and its filings give detailed insight into how it reports financial performance, manages risks, and documents material events related to its Organ Care System (OCS) and National OCS Program (NOP).
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue from OCS products and NOP services, operating expenses, and discussions of risk factors such as dependence on the OCS platform, regulatory approvals, logistics capabilities, indebtedness, and healthcare policy changes. Form 8-K current reports capture material events, including quarterly financial results, aircraft acquisitions for the NOP fleet, and other significant corporate developments.
TransMedics’ filings also discuss the acquisition and use of fixed-wing aircraft for transporting donor organs, its collaboration and logistics strategy, and the regulatory environment for both its medical devices and aviation transportation services. Disclosures highlight the importance of maintaining FDA and other regulatory approvals for OCS products and licenses for aviation operations.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points from lengthy filings, helping users quickly identify information on topics such as revenue drivers, risk factors, and logistics investments. Real-time updates from EDGAR, along with easy access to insider transaction reports on Form 4 and proxy materials on executive and governance matters, make this page a focused resource for analyzing TMDX’s regulatory record and corporate reporting over time.
TransMedics Group, Inc. filed an initial ownership report for executive Giovanni Cecere, who serves as Chief Commercial Officer. This Form 3 states that no securities are beneficially owned, meaning Cecere reports holding no TransMedics Group stock or derivative securities as of the event date.
TransMedics Group, Inc. announced leadership transitions in its commercial and legal functions. The Board appointed Giovanni Cecere as Chief Commercial Officer effective February 2, 2026, succeeding Tamer Khayal, M.D., who will become Senior Vice President of International on the same date.
The Board also appointed Matthew Forsyth as Senior Vice President, General Counsel & Corporate Secretary effective March 9, 2026 or his actual start date. Current General Counsel Anil Ranganath will move to a non-executive employee role until June 7, 2026 and then serve as a non-employee consultant until September 7, 2026. His equity awards will continue to vest during his service, and he will receive an annualized consultant fee of
TransMedics Group, Inc. has signed a long-term lease with BioMed Realty for approximately 498,286 square feet at 188 Assembly Park Drive in Somerville, Massachusetts, which will become its new headquarters and house research, development, lab, manufacturing, assembly, vivarium, office and related functions. The lease term begins on January 8, 2026, with base rent starting on the later of January 1, 2028 or 24 months after term commencement, and running for 192 months from that rent start date.
Initial annual base rent is approximately $23.9 million, increasing 2% each year over the initial term, and the company is expected to bear about 100% of operating and tax expenses for the premises. TransMedics has provided an approximately $18 million letter of credit as a security deposit and holds two 10-year extension options plus a six-month extension option, all subject to customary conditions. Separately, on January 8, 2026, the company acquired two parcels adjacent to the new site in Somerville for $15.0 million each, plus related costs.
TransMedics Group, Inc. (TMDX)11/25/2025, the officer exercised a stock option for 3,000 shares of common stock at an exercise price of $93.88 per share and then sold 3,000 shares of common stock at a weighted average price of $145.22 per share. After these transactions, the officer beneficially owned 13,955 shares of TransMedics common stock directly and held 7,420 stock options directly. The option referenced vested 25% on June 5, 2024 and will continue to vest in equal monthly installments over three years thereafter, subject to continued service.
TransMedics Group, Inc. (TMDX)
TransMedics Group (TMDX) Form 4: A director exercised 4,142 stock options at $0.70 on 10/29/2025 and sold 4,142 common shares at $130.45 the same day under a Rule 10b5-1 trading plan entered on November 6, 2024. After these transactions, the director directly owned 2,866 shares. The option was fully vested and carried a stated expiration of 02/16/2026, with zero derivative securities remaining afterward.
TransMedics Group (TMDX) reported strong third-quarter results. Total revenue rose to $143.8 million, up from $108.8 million a year ago, with net income of $24.3 million versus $4.2 million last year. Gross profit reached $84.6 million, reflecting higher product and service activity across the Organ Care System (OCS) platform.
Growth was concentrated in the United States, where OCS transplant revenue totaled $139.0 million, led by liver at $107.9 million and heart at $27.4 million. Diluted EPS was $0.66 (basic $0.71). Year‑to‑date, revenue was $444.7 million with $84.9 million of net income and $158.3 million in cash from operations.
The balance sheet strengthened with $466.2 million in cash and $355.2 million in stockholders’ equity. The company reported $452.1 million net carrying value of its 1.50% convertible senior notes due 2028 and $54.6 million in long‑term bank debt. As of October 17, 2025, 34,174,325 common shares were outstanding.
TransMedics Group, Inc. (TMDX) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company specifies the information is being furnished, not filed, meaning it is not subject to Section 18 liability and will only be incorporated into other filings if expressly referenced. The common stock trades on the Nasdaq Global Market under the symbol TMDX.
TransMedics Group, Inc. filed a Form 8-K disclosing a material event: the company considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program. The filing identifies this as a material event and is signed by Gerardo Hernandez, Chief Financial Officer and Treasurer on
TransMedics Group’s President and CEO Waleed H. Hassanein, through the Waleed H. Hassanein Revocable Trust, reported open‑market purchases of the company’s common stock. On August 6, 2025, the trust bought 8,400 shares at a weighted average price of $118.68.
On August 7, 2025, the trust made additional open‑market purchases of 6,617 shares at a weighted average price of $116.08 and 1,858 shares at a weighted average price of $116.85. After these transactions, the trust indirectly held 486,234 shares, and Hassanein directly held 121,424 shares.
FAQ
What is the current stock price of Transmedics Group (TMDX)?
What is the market cap of Transmedics Group (TMDX)?
